M

Marker Therapeutics
D

MRKR

3.58000
USD
0.66
(22.60%)
Market Closed
Volume
0
EPS
-3
Div Yield
-
P/E
-3
Market Cap
31,946,094
Related Instruments
    A
    AXON
    -5.56
    (-0.92%)
    599.18 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    G
    GH
    -1.065
    (-3.53%)
    29.130 USD
    I
    IONS
    -2.970
    (-7.97%)
    34.290 USD
    M
    MGTX
    -0.18000
    (-2.71%)
    6.47000 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    X
    XBIT
    -0.31000
    (-4.45%)
    6.66000 USD
    More
News

Title: Marker Therapeutics

Sector: Healthcare
Industry: Biotechnology
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.